Cargando…

Antibodies against Malondialdehyde in Haemodialysis Patients and Its Association with Clinical Outcomes: Differences between Subclasses and Isotypes

Patients on haemodialysis (HD-patients) have an increased risk of premature death. Low levels of IgM antibodies against malondialdehyde (anti-MDA) are associated with increased risk of cardiovascular disease (CVD) with underlying potential mechanisms described. Here, we studied subclasses and isotyp...

Descripción completa

Detalles Bibliográficos
Autores principales: Samal, Shailesh Kumar, Qureshi, Abdul Rashid, Rahman, Mizanur, Stenvinkel, Peter, Frostegård, Johan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7141181/
https://www.ncbi.nlm.nih.gov/pubmed/32168733
http://dx.doi.org/10.3390/jcm9030753
_version_ 1783519140141596672
author Samal, Shailesh Kumar
Qureshi, Abdul Rashid
Rahman, Mizanur
Stenvinkel, Peter
Frostegård, Johan
author_facet Samal, Shailesh Kumar
Qureshi, Abdul Rashid
Rahman, Mizanur
Stenvinkel, Peter
Frostegård, Johan
author_sort Samal, Shailesh Kumar
collection PubMed
description Patients on haemodialysis (HD-patients) have an increased risk of premature death. Low levels of IgM antibodies against malondialdehyde (anti-MDA) are associated with increased risk of cardiovascular disease (CVD) with underlying potential mechanisms described. Here, we studied subclasses and isotypes of anti-MDA in 210 HD-patients with mortality as outcome (56% men, median age 66, Interquartile range (IQR) 51–74 years, vintage time 29 (15–58) months, mean follow up period of 41 (20–60)months). Patients were also divided into inflamed c-reactive protein (CRP >5.6 mg/mL) and non-inflamed. Antibody levels were measured by ELISA. In multivariate risk analysis, patients in low tertile of IgM anti-MDA sub-distribution hazard ratio (sHR 0.54); 95% confidence interval (CI: 0.34–0.89) inversely and significantly associated with all-cause mortality after five years, after adjusting for confounders. Low tertile of IgG (sHR 0.48, 95%CI: 0.25–0.90, p = 0.02) and IgG1 (sHR 0.50, CI: 0.24–1.04, p = 0.06) was associated low mortality among non-inflamed patients. In contrast, anti-MDA IgG2 among inflamed patients was significantly associated with increased mortality, IgG2(sHR 2.33, CI: 1.16–4.68, p = 0.01). IgM anti-MDA was a novel biomarker among HD-patients with low levels being associated with mortality, while low levels of IgG and IgG1 but not IgA anti-MDA were associated with mortality only among non-inflamed patients. IgG2 anti-MDA was a significant risk marker among inflamed patients, which could be related to infection.
format Online
Article
Text
id pubmed-7141181
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-71411812020-04-10 Antibodies against Malondialdehyde in Haemodialysis Patients and Its Association with Clinical Outcomes: Differences between Subclasses and Isotypes Samal, Shailesh Kumar Qureshi, Abdul Rashid Rahman, Mizanur Stenvinkel, Peter Frostegård, Johan J Clin Med Article Patients on haemodialysis (HD-patients) have an increased risk of premature death. Low levels of IgM antibodies against malondialdehyde (anti-MDA) are associated with increased risk of cardiovascular disease (CVD) with underlying potential mechanisms described. Here, we studied subclasses and isotypes of anti-MDA in 210 HD-patients with mortality as outcome (56% men, median age 66, Interquartile range (IQR) 51–74 years, vintage time 29 (15–58) months, mean follow up period of 41 (20–60)months). Patients were also divided into inflamed c-reactive protein (CRP >5.6 mg/mL) and non-inflamed. Antibody levels were measured by ELISA. In multivariate risk analysis, patients in low tertile of IgM anti-MDA sub-distribution hazard ratio (sHR 0.54); 95% confidence interval (CI: 0.34–0.89) inversely and significantly associated with all-cause mortality after five years, after adjusting for confounders. Low tertile of IgG (sHR 0.48, 95%CI: 0.25–0.90, p = 0.02) and IgG1 (sHR 0.50, CI: 0.24–1.04, p = 0.06) was associated low mortality among non-inflamed patients. In contrast, anti-MDA IgG2 among inflamed patients was significantly associated with increased mortality, IgG2(sHR 2.33, CI: 1.16–4.68, p = 0.01). IgM anti-MDA was a novel biomarker among HD-patients with low levels being associated with mortality, while low levels of IgG and IgG1 but not IgA anti-MDA were associated with mortality only among non-inflamed patients. IgG2 anti-MDA was a significant risk marker among inflamed patients, which could be related to infection. MDPI 2020-03-11 /pmc/articles/PMC7141181/ /pubmed/32168733 http://dx.doi.org/10.3390/jcm9030753 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Samal, Shailesh Kumar
Qureshi, Abdul Rashid
Rahman, Mizanur
Stenvinkel, Peter
Frostegård, Johan
Antibodies against Malondialdehyde in Haemodialysis Patients and Its Association with Clinical Outcomes: Differences between Subclasses and Isotypes
title Antibodies against Malondialdehyde in Haemodialysis Patients and Its Association with Clinical Outcomes: Differences between Subclasses and Isotypes
title_full Antibodies against Malondialdehyde in Haemodialysis Patients and Its Association with Clinical Outcomes: Differences between Subclasses and Isotypes
title_fullStr Antibodies against Malondialdehyde in Haemodialysis Patients and Its Association with Clinical Outcomes: Differences between Subclasses and Isotypes
title_full_unstemmed Antibodies against Malondialdehyde in Haemodialysis Patients and Its Association with Clinical Outcomes: Differences between Subclasses and Isotypes
title_short Antibodies against Malondialdehyde in Haemodialysis Patients and Its Association with Clinical Outcomes: Differences between Subclasses and Isotypes
title_sort antibodies against malondialdehyde in haemodialysis patients and its association with clinical outcomes: differences between subclasses and isotypes
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7141181/
https://www.ncbi.nlm.nih.gov/pubmed/32168733
http://dx.doi.org/10.3390/jcm9030753
work_keys_str_mv AT samalshaileshkumar antibodiesagainstmalondialdehydeinhaemodialysispatientsanditsassociationwithclinicaloutcomesdifferencesbetweensubclassesandisotypes
AT qureshiabdulrashid antibodiesagainstmalondialdehydeinhaemodialysispatientsanditsassociationwithclinicaloutcomesdifferencesbetweensubclassesandisotypes
AT rahmanmizanur antibodiesagainstmalondialdehydeinhaemodialysispatientsanditsassociationwithclinicaloutcomesdifferencesbetweensubclassesandisotypes
AT stenvinkelpeter antibodiesagainstmalondialdehydeinhaemodialysispatientsanditsassociationwithclinicaloutcomesdifferencesbetweensubclassesandisotypes
AT frostegardjohan antibodiesagainstmalondialdehydeinhaemodialysispatientsanditsassociationwithclinicaloutcomesdifferencesbetweensubclassesandisotypes